Construction begins on RNA research and manufacturing facility in NSW

Construction has officially commenced on New South Wales’ first RNA research and pilot manufacturing facility at Macquarie University.

Supported by a $96 million investment from the NSW Government, this state-of-the-art facility is expected to revolutionise healthcare by developing advanced RNA-based vaccines and therapeutics.

The facility will provide sovereign capability in RNA research, enabling the design, testing, and production of RNA-based drugs for clinical trials. It is set to be completed by 2026 and will further position NSW as a leader in the health and life sciences sectors.

NSW Premier Chris Minns highlighted the importance of the project, noting that it will play a critical role in boosting Australia’s preparedness for future pandemics and advancing healthcare innovation. “This facility will allow us to accelerate the development of crucial vaccines and treatments, ensuring we have the infrastructure to meet the challenges of tomorrow,” Minns said.

Deputy Premier and Minister for Science, Innovation, and Technology Paul Toole also expressed optimism, emphasising how this development would strengthen the state’s research and manufacturing capabilities. “Having a local RNA facility is key to making sure we have control over critical medical technologies, and it’s also a boost for our skilled workforce,” Toole added.

RNA technology, which has been integral in the development of COVID-19 vaccines, is seen as the future of therapeutic innovation. The new facility will enable Australia to play a leading role in this rapidly advancing field and will support the production of therapies for cancer, genetic disorders, and other diseases.